Use code NEW15 and save 15% Sitewide.
Cookies
We use cookies for analytics to understand how the site is used and to improve it. See our privacy policy.
Legal & Compliance
Two vials with the same peptide name and the same listed purity can still belong to two completely different regulatory worlds. Research-grade and pharmacy-grade describe parallel supply chains with different rules about what gets tested, what gets documented, and who is accountable for what — and the gap shows up in the impurity profile, not the molecular weight.
Legal & Compliance
FDA's Pharmacy Compounding Advisory Committee will meet July 23-24, 2026 to discuss whether seven research peptides — BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, and Epitalon — should be added to the section 503A Bulks List. This research-use-only reference explains what the 503A Bulks List actually is, what's on the July 2026 agenda, the three nomination categories used during evaluation, the PCAC's advisory role versus FDA's final-decision authority, and what the outcomes mean — and don't mean — for research-grade peptide supply.